Nervous system disorder – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:16:53 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Nervous system disorder – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Effects of Dexmedetomidine on Brain Fluid Flow and Activity in Patients with Neurodegenerative Diseases, Delirium, or Acute Neurological Conditions https://clinicaltrials.eu/trial/study-on-the-effects-of-dexmedetomidine-on-brain-fluid-flow-and-activity-in-patients-with-neurodegenerative-diseases-delirium-or-acute-neurological-conditions/ Wed, 29 Apr 2026 15:05:47 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-dexmedetomidine-on-brain-fluid-flow-and-activity-in-patients-with-neurodegenerative-diseases-delirium-or-acute-neurological-conditions/ This clinical trial is focused on studying the effects of a medication called Dexmedetomidine on the brain. The diseases being studied include neurodegenerative disease, delirium, and acute neurological disease. The purpose of the study is to understand how this medication influences brain functions such as blood flow and the movement of cerebrospinal fluid, which is a clear liquid surrounding the brain and spinal cord. The study will use a technique called functional Magnetic Resonance Imaging (MRI) to observe these effects.

Participants in the study will receive Dexmedetomidine through an intravenous infusion, which means it will be administered directly into a vein. The study will observe changes in brain activity and blood flow while participants are awake and under different levels of sedation caused by the medication. The study will also use electroencephalography (EEG), a method to record electrical activity of the brain, to gather more information about how the brain functions during these different states.

The study aims to gather data on how Dexmedetomidine affects brain signals and other bodily functions, such as blood pressure and heart rate. This information will help researchers understand the potential benefits and effects of the medication on brain health, particularly in relation to the diseases being studied. The study will also look at how the medication affects various biomarkers, which are substances in the body that can indicate how well the body is functioning or responding to treatment.

]]> Study on the Effects of Cannabidiol on the Central Nervous System in Healthy Male Participants https://clinicaltrials.eu/trial/study-on-the-effects-of-cannabidiol-on-the-central-nervous-system-in-healthy-male-participants/ Wed, 29 Apr 2026 15:05:35 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-cannabidiol-on-the-central-nervous-system-in-healthy-male-participants/ This clinical trial is focused on understanding the effects of a substance called cannabidiol on the central nervous system (CNS) in healthy male participants. Cannabidiol, often referred to as CBD, is a compound found in cannabis plants. The study will use a flavored oil form of CBD, known as Clinican CBD 10% oil flavored, and will compare its effects to a placebo. The main goal is to observe how different doses of CBD, specifically 30 mg and 700 mg, influence certain brain functions and excitability, which refers to how easily the brain responds to stimuli.

Participants will take part in a series of tests designed to measure various aspects of brain activity and function. These tests include the NeuroCart test battery and Transcranial Magnetic Stimulation (TMS), which are methods used to assess brain performance and excitability. The study will look at how CBD affects tasks related to eye movements, memory, and body balance, among others. The trial will also monitor any side effects and changes in vital signs, such as heart rate and blood pressure, throughout the study period.

The study is structured as a randomized, double-blind, placebo-controlled, 3-way cross-over trial. This means that participants will receive different treatments in a random order, and neither the participants nor the researchers will know which treatment is being administered at any given time. The trial aims to provide insights into how CBD might influence brain function and could potentially inform future research or treatments involving CBD.

]]> Study on the Physical Impact of Multiple Sclerosis and Continued Access to Ocrelizumab for Patients Previously in a Related Study https://clinicaltrials.eu/trial/study-on-the-physical-impact-of-multiple-sclerosis-and-continued-access-to-ocrelizumab-for-patients-previously-in-a-related-study/ Wed, 29 Apr 2026 15:01:59 +0000 https://clinicaltrials.eu/trial/study-on-the-physical-impact-of-multiple-sclerosis-and-continued-access-to-ocrelizumab-for-patients-previously-in-a-related-study/ This clinical trial focuses on studying the effects of Multiple Sclerosis and providing continued access to a treatment called Ocrelizumab. Multiple Sclerosis is a condition that affects the brain and spinal cord, leading to a range of symptoms such as problems with vision, arm or leg movement, sensation, or balance. The treatment being studied, Ocrelizumab, is available in two forms: a 920 mg solution for injection and a 300 mg concentrate for solution for infusion. The purpose of the study is to understand the physical impact of Multiple Sclerosis from the patient’s perspective and to ensure that patients who were previously part of a related study can continue receiving Ocrelizumab.

Participants in this study will receive Ocrelizumab either as an injection under the skin or as an infusion into a vein. The study will last for a period of up to five years, during which the physical effects of Multiple Sclerosis on patients will be evaluated. The study will also monitor the number of participants who continue to receive Ocrelizumab and any side effects they may experience. This study is an extension of previous research, allowing patients who do not have access to Ocrelizumab locally to continue their treatment.

The study aims to gather information on how patients perceive the physical impact of Multiple Sclerosis while continuing their treatment with Ocrelizumab. This information will help in understanding the long-term effects of the treatment and its impact on patients’ quality of life. Participants will be monitored for any serious side effects or adverse events that may occur during the study period. The study is designed to provide valuable insights into the management of Multiple Sclerosis and the role of Ocrelizumab in improving patient outcomes.

]]> Study of KYV-101 Therapy for Patients with Refractory Primary and Secondary Progressive Multiple Sclerosis https://clinicaltrials.eu/trial/study-of-kyv-101-therapy-for-patients-with-refractory-primary-and-secondary-progressive-multiple-sclerosis/ Wed, 29 Apr 2026 14:58:48 +0000 https://clinicaltrials.eu/trial/study-of-kyv-101-therapy-for-patients-with-refractory-primary-and-secondary-progressive-multiple-sclerosis/ This clinical trial is focused on studying a treatment for Primary and Secondary Progressive Multiple Sclerosis, a condition where the immune system mistakenly attacks the protective covering of nerves, leading to worsening physical disability. The treatment being tested is called KYV-101, which is a type of therapy that uses the patient’s own immune cells, specifically T-cells, that are modified to better target and fight the disease. This therapy is known as Anti-CD19 CAR T-cell Therapy, where CAR stands for Chimeric Antigen Receptor, a special receptor added to the T-cells to help them recognize and attack the disease more effectively.

The purpose of the study is to evaluate how effective KYV-101 is in treating this form of multiple sclerosis. Participants in the study will receive the treatment and be monitored over a period of time to see how their condition changes. The study will look at various aspects, such as changes in physical disability, the number of relapses, and any changes observed in brain scans using MRI (Magnetic Resonance Imaging). The study will also monitor the presence of specific cells and proteins in the body to understand how the treatment is working.

Throughout the study, participants will receive either the KYV-101 treatment or a placebo, and their progress will be tracked to assess the treatment’s impact. The study aims to provide valuable information on whether this new therapy can help manage or slow down the progression of Primary and Secondary Progressive Multiple Sclerosis. The study is expected to continue until 2028, with recruitment starting in 2024.

]]> Continued Access Study for Patients with Neurological Disease Using Ocrelizumab and Drug Combination https://clinicaltrials.eu/trial/continued-access-study-for-patients-with-neurological-disease-using-ocrelizumab-and-drug-combination/ Wed, 29 Apr 2026 14:30:00 +0000 https://clinicaltrials.eu/trial/continued-access-study-for-patients-with-neurological-disease-using-ocrelizumab-and-drug-combination/ This clinical trial is focused on providing continued access to treatment for patients with a neurological disease. The study involves the use of a medication called Ocrelizumab, which is administered as a concentrate for solution for infusion or as a solution for injection. The purpose of the study is to ensure that patients who were previously enrolled in a related study can continue receiving their treatment if they do not have access to it locally.

In addition to Ocrelizumab, the study also involves other medications, including Lidocaine Hydrochloride Monohydrate, Methylprednisolone Acetate, and Dexamethasone Acetate. These medications are used in various forms, such as oral, intravenous, and subcutaneous routes, to support the treatment of the neurological condition. The study does not provide new treatments but continues the existing therapy for those who have been benefiting from it.

Participants in this study will continue their treatment over a period of time, ensuring they receive the necessary care without interruption. The study is designed to be an extension of previous research, allowing patients to maintain their health and manage their condition effectively. The trial aims to provide a seamless transition for patients who are already on these therapies, ensuring they have ongoing access to their medication.

]]> Study Comparing Gadoquatrane with Gadoteric Acid, Gadobutrol, and Gadoteridol for MRI in Adults with Brain or Spinal Cord Issues https://clinicaltrials.eu/trial/study-comparing-gadoquatrane-with-gadoteric-acid-gadobutrol-and-gadoteridol-for-mri-in-adults-with-brain-or-spinal-cord-issues/ Wed, 29 Apr 2026 14:26:56 +0000 https://clinicaltrials.eu/trial/study-comparing-gadoquatrane-with-gadoteric-acid-gadobutrol-and-gadoteridol-for-mri-in-adults-with-brain-or-spinal-cord-issues/ This clinical trial is focused on evaluating the effectiveness and safety of a new contrast agent called gadoquatrane for use in MRI scans. The study is specifically looking at adults who have known or suspected issues with their brain or spinal cord, which are part of the central nervous system. The trial will compare gadoquatrane to other approved contrast agents that are already used in medical practice, such as gadoteric acid, gadobutrol, and gadoteridol. These agents help improve the clarity of MRI images, making it easier for doctors to see and diagnose problems.

The purpose of the study is to determine if gadoquatrane is as effective as the existing contrast agents. Participants in the study will undergo two MRI scans: one using gadoquatrane and another using one of the other approved contrast agents. The study is designed to be double-blind, meaning neither the participants nor the researchers will know which contrast agent is being used during each scan. This helps ensure that the results are unbiased and reliable.

Throughout the study, researchers will assess various aspects of the MRI images, such as how well the contrast agent highlights different areas and how clearly it defines the structures within the brain or spinal cord. The study will also monitor any side effects or adverse reactions to the contrast agents. The goal is to provide valuable information about the potential benefits and risks of using gadoquatrane in MRI scans for diagnosing central nervous system conditions.

]]> Study on Metformin for Delaying Progression in Non-Active Progressive Multiple Sclerosis Patients https://clinicaltrials.eu/trial/study-on-metformin-for-delaying-progression-in-non-active-progressive-multiple-sclerosis-patients/ Wed, 29 Apr 2026 14:24:31 +0000 https://clinicaltrials.eu/trial/study-on-metformin-for-delaying-progression-in-non-active-progressive-multiple-sclerosis-patients/ This clinical trial is focused on studying the effects of adding metformin to the treatment of patients with Progressive Multiple Sclerosis (PMS). Metformin is a medication commonly used to treat diabetes, and researchers are investigating whether it can help slow down the progression of PMS. The study will compare the effects of metformin with a placebo, which is a substance with no active medication, to see if metformin can improve walking speed and other health measures over a period of 96 weeks.

Participants in the study will receive either metformin or a placebo and will be monitored for changes in their condition. The main focus is to see if metformin can delay the progression of the disease, as measured by walking speed. Other aspects of health, such as cognitive function, hand function, and quality of life, will also be assessed. These assessments will be done using various tests and measures, including the Expanded Disability Status Scale (EDSS) and the Symbol Digit Modalities Test (SDMT).

The study will also use MRI scans to look at changes in brain volume and other brain characteristics over time. The trial is designed to be “triple-blind,” meaning that the participants, the healthcare providers, and the researchers do not know who is receiving the metformin or the placebo. This helps ensure that the results are unbiased and reliable. The study aims to provide valuable information on whether metformin can be an effective add-on treatment for people with PMS.

]]>